New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

OKYO Pharma LTD

Contributing Author

Recent Articles by OKYO Pharma LTD

Jan-23	FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain OKYO -6.33% GlobeNewswire
Jan-05	OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer OKYO GlobeNewswire
Dec-19	OKYO Pharma to Ring the Opening Bell at Nasdaq OKYO GlobeNewswire
Dec-15	OKYO Pharma Announces Chairman and Founder Acquires Shares OKYO GlobeNewswire
Dec-11	OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain OKYO GlobeNewswire
Dec-03	OKYO Pharma Announces Chairman and Founder Acquires Shares OKYO GlobeNewswire
Nov-21	OKYO Pharma Announces Chairman and Founder Acquires Shares OKYO GlobeNewswire
Nov-18	OKYO Pharma to Present at OIS XV in San Diego OKYO GlobeNewswire
Oct-29	OKYO Pharma to Present at BIO-Europe 2025 in Vienna OKYO GlobeNewswire
Oct-16	OKYO Pharma Announces Chairman and Founder Acquires Shares OKYO GlobeNewswire
Sep-22	OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain OKYO GlobeNewswire
Jul-17	OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain OKYO GlobeNewswire
Jul-16	OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain OKYO GlobeNewswire
Jun-11	OKYO Pharma to Present at the Bio International Convention OKYO GlobeNewswire
May-19	OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit OKYO GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.